Health Care • Biotechnology: Laboratory Analytical Instruments
$157.00 ▼ -8.78
(-5.30%)
MKT CAP: $18.50B • VOL: 3.18M
52W L $81 52W H $169
RVTY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-28 | FY 2024
FILED 2024-12-29 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.86B | $2.76B | $2.75B |
| YoY Revenue Growth % | +3.7% | +0.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $356.6M | $346.7M | $300.6M |
| Operating Margin % | 12.5% | 12.6% | 10.9% |
| Net Income (GAAP) | $241.2M | $270.4M | $693.1M |
| EBITDA (Normalized) | $415.5M | $416.1M | $399.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $582.9M | $628.3M | $91.3M |
| Capital Expenditures (CapEx) | $73.5M | $86.6M | $123.8M |
| Free Cash Flow (FCF) | $509.4M | $541.7M | -$32.5M |
| FCF Margin % | 17.8% | 19.7% | -1.2% |
| Return on Invested Capital (ROIC %) | 3.1% | 2.8% | 3.9% |
| Cash & Short-Term Equivalents | $919.9M | $1.16B | — |
| Total Debt (Short + Long Term) | $2.63B | $3.15B | $2.38B |
| Total Stockholders' Equity | $7.25B | $7.67B | $4.88B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RVTY.